Novellus
Novellus
Precision oncology company focused on developing BRAF inhibitor PLX-8394.
About
What does Novellus do?
Novellus Ltd. is an Israeli clinical-stage biotechnology company focused on precision oncology. Their lead program, PLX-8394, is a BRAF inhibitor with a differentiated mechanistic profile, licensed from Plexxikon. The company utilizes a functional genomics platform called FACT to identify patient subpopulations likely to respond to specific drugs. Funds raised will support the clinical development of PLX-8394 for indications like BRAF fusions and certain BRAF-mutated gliomas, and expand their pi…
What is Novellus's revenue?
StartupHub estimates Novellus's annual revenue at $17.6M (range $4.4M to $27.5M, 32% confidence), based on comparable companies in the sector.
What is Novellus's valuation?
StartupHub estimates Novellus's effective valuation at $218.9M (range $142.5M to $342.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Novellus raised?
Novellus has raised a total of $57M in funding. The most recent round on record is Series C.
Where is Novellus headquartered?
Novellus is headquartered in Jerusalem, Israel.
What industry does Novellus operate in?
Novellus operates in Healthcare, Biotechnology, Oncology.
No comments yet. Be the first to share your take.